World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
33674
World Ranking
13022
National Ranking
1214

Gordon J. S. Rustin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gordon J. S. Rustin sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 298 publications — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gordon J. S. Rustin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gordon J. S. Rustin sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gordon J. S. Rustin is affiliated with Mount Vernon Hospital in the United Kingdom. Their research primarily focuses on medicine, with significant contributions in surgery, pulmonary and respiratory medicine, reproductive medicine, rheumatology, and obstetrics and gynecology. The main topics addressed in their work include testicular diseases and treatments, sarcoma diagnosis and treatment, ovarian cancer diagnosis and treatment, urologic and reproductive health conditions, intraperitoneal and appendiceal malignancies, renal cell carcinoma treatment, as well as adrenal and paraganglionic tumors.

They have contributed extensively to the scientific literature, with notable publications including:

  • Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994, 2023, Journal of Clinical Oncology
  • Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST), 2022, Journal of Clinical Oncology
  • Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial, 2021, ESMO Open
  • A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer, 2020, Gynecologic Oncology
  • Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial, 2020, Gynecologic Oncology

Their frequent co-authors include:

  • Johnathan Joffe
  • Fay Cafferty
  • Richard Kaplan
  • Robert Huddart
  • S.A. Sohaib

Research by Gordon J. S. Rustin has been published predominantly in the following venues:

  • Journal of Clinical Oncology
  • Gynecologic Oncology
  • ESMO Open
  • European Journal of Cancer
  • Practical Radiation Oncology

Their work covers an extensive range of clinical and therapeutic areas involving oncology, especially focusing on cancers related to reproductive and urologic systems. Their research frequently addresses clinical trials and randomized studies offering insight into treatment efficacy and surveillance strategies in cancer care.

Best Publications

  • Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations

    Anwar R. Padhani;Guoying Liu;Dow Mu-Koh;Thomas L. Chenevert

  • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Carboplatin or cisplatin

    A.H. Calvert;A. Horwich;E.S. Newlands;R. Begent

  • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

    Ajay K. Kakkar;Mark N. Levine;Zbigniew Kadziola;Nicholas R. Lemoine

  • Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.

    Amit M. Oza;Adrian D. Cook;Jacobus Pfisterer;Andrew Embleton

  • Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.

    Gordon J.S. Rustin;Maria E.L. Van Der Burg;Clare L. Griffin;David Guthrie

  • Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial

    M. K B Parmar;M. Adams;M. Balestrino;K. Bertelsen

  • Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

    Gordon John Sampson Rustin;Ignace Vergote;Elizabeth Eisenhauer;Eric Pujade-Lauraine

  • Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

    E. S. Newlands;G. R. Blackledge;J. A. Slack;G. J. Rustin

  • The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

    Martin O Leach;K Brindle;J Evelhoch;John R Griffiths

  • Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial

    R.T.D. Oliver;Mason;G.M. Mead;H. von der Maase

  • Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

    Jonathan A Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

    G. J. S. Rustin;A. E. Nelstrop;P. Mcclean;M. F. Brady

  • Role of tumour markers in monitoring epithelial ovarian cancer.

    T Meyer;G J S Rustin

  • CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

    M.J. Duffy;J.M. Bonfrer;J. Kulpa;G.J.S. Rustin

  • Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study

    G. J. S. Rustin;A. E. Nelstrop;M. K. Tuxen;H. E. Lambert

  • Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging

    Susan M. Galbraith;Ross J. Maxwell;Martin A. Lodge;Gillian M. Tozer

  • Reproducibility of dynamic contrast‐enhanced MRI in human muscle and tumours: comparison of quantitative and semi‐quantitative analysis

    Susan M Galbraith;Martin A Lodge;N Jane Taylor;Gordon J S Rustin

  • Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results

    Gordon J.S. Rustin;Susan M. Galbraith;Helen Anderson;Michael Stratford

Frequent Co-Authors

Jonathan A. Ledermann
Jonathan A. Ledermann University College London
Michael Friedlander
Michael Friedlander University of New South Wales
Ursula A. Matulonis
Ursula A. Matulonis Harvard University
Anwar R. Padhani
Anwar R. Padhani Northwood University
Clare L. Scott
Clare L. Scott Walter and Eliza Hall Institute of Medical Research
Mark Bower
Mark Bower Imperial College London
Gordon C Jayson
Gordon C Jayson University of Manchester
Stan B. Kaye
Stan B. Kaye Royal Marsden NHS Foundation Trust
Robert Huddart
Robert Huddart Institute of Cancer Research

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in exploring alternative healthcare careers beyond medical school, there are many flexible and accessible pathways available online. For those seeking advanced roles in nursing, direct msn programs online allow non-nurses to fast-track their education and enter the profession at a graduate level.

Entry into healthcare programs can vary in competitiveness. Some students might benefit from considering the easiest nursing programs to get into, which offer more inclusive admission criteria while still delivering quality education.

Not all healthcare careers require direct patient care. Medical billing and coding is a growth field with strong remote work potential. Many institutions offer online certificates and degrees, and you can find medical billing and coding schools with financial aid to help make your education more affordable.

Finally, some programs have streamlined testing requirements. If you're wondering “do i need to take the teas test for lpn?”—there are schools that no longer require the TEAS or HESI for admission, making it easier to begin your nursing journey.

Best Scientists Citing Gordon J. S. Rustin

Trending Scientists

Recently Published Articles